Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03528408
Recruitment Status : Recruiting
First Posted : May 17, 2018
Last Update Posted : November 18, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Suthee Rapisuwon, Hoosier Cancer Research Network

Brief Summary:
This is an open-label, multi-site, single-arm Phase 2 study of adjuvant nivolumab combined with ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metastatic disease. All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, patient request to discontinue or completion of treatment. Subjects may receive up to 25 doses of nivolumab and 8 doses of ipilimumab

Condition or disease Intervention/treatment Phase
Melanoma Drug: Nivolumab Drug: Ipilimumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Actual Study Start Date : July 26, 2018
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : June 2023


Arm Intervention/treatment
Experimental: Nivolumab and Ipilimumab
All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks.
Drug: Nivolumab
Nivolumab 240 mg IV over 30 minutes given Day 1, 14 and 28 of each Cycle
Other Name: Opdivo

Drug: Ipilimumab
Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
Other Name: Yervoy




Primary Outcome Measures :
  1. 3 year Relapse Free Survival (RFS) [ Time Frame: 36 months ]
    RFS is defined as time from registration to recurrence of disease or death from any cause.


Secondary Outcome Measures :
  1. Median RFS [ Time Frame: 12 months ]
    RFS is defined as time from registration to recurrence of disease or death from any cause

  2. Overall Survival (OS) [ Time Frame: 12 months ]
    OS is defined as the time from registration until death from any cause

  3. 3 year OS [ Time Frame: 36 months ]
    OS is defined as the time from registration until death from any cause

  4. Assess Adverse Events [ Time Frame: 36 months ]
    Grade 3 and 4 toxicities as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  2. Age ≥ 18 years at the time of consent. No dosing or adverse event data are currently available on the use of ipilimumab in combination with nivolumab in patients < 18 years of age.
  3. ECOG Performance Status of 0-1 within 28 days prior to registration.
  4. Patients must have clinically confirmed ocular melanoma diagnosed by a retinal specialist or ocular oncologist. NOTE: Patients with cutaneous melanoma, acral melanoma, mucosal melanoma, or conjunctival melanoma are ineligible.
  5. Patients must have ocular melanoma that is considered high-risk for recurrence as defined by one of the following criteria:

    • Gene Expression Profile using 15-gene panel (Castle Bioscience) and be classified as Class 2, or
    • 3-year recurrent risk of more than 50% as defined by Impact Genetics, or
    • Monosomy of chromosome 3 with apical tumor height > 8mm (53).
  6. Archival tumor tissue is required for subjects that have had enucleation; subjects that have had enucleation but do not have available archival tissue are not eligible for participation. Archival tissue is required if available for subjects that have not had enucleation; if not available these patients are still eligible.
  7. Patients must have undergone an adequate treatment for the primary ocular melanoma deemed appropriate by the treating physician.
  8. All disease must be treated with no clinical, or radiologic evidence of residual ocular melanoma. All participants must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to registration. Imaging studies must include CT or MRI scans of the chest, abdomen, and pelvis. Brain MRI should be performed only as clinically indicated. NOTE: Participants with equivocal nodes ≥ 10 mm and < 15 mm in a short axis may be eligible after if confirmation with histology/cytology is available. If risk of biopsy is too high or biopsy is not feasible, two sequential CT or MRI scans should be available and showing no signs of progressive and measurable disease or PET/CT demonstrating no FDG uptake. The second scan should occur at least 4 weeks after the initial scan. Lymph nodes ≥ 10 mm in a short axis are defined as pathological. Nodes that have a short axis <10 mm are considered non-pathological.
  9. Patients must be registered within 180 days of the last treatment performed to render the patient free of disease.
  10. Patient may have received prior radiation therapy to the primary site, including after the surgical resection. No systemic radiation for metastatic ocular melanoma is permitted.
  11. Subject re-enrollment: This study permits the re-enrollment of a participant who has discontinued the study as a screen failure. If re-enrolled, the participant must be re-consented
  12. Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 28 days prior to registration.

    • Absolute Neutrophil Count (ANC) ≥ 1,500 cells/mm3
    • Platelets ≥ 100,000 cells/mm3
    • Hemoglobin (Hgb) ≥ 9 g/dL (NOTE: The use of transfusion or to achieve Hgb ≥ 10 g/dl is acceptable)
    • Serum creatinine ≤ 1.5 x institutional upper limit normal (IULN) OR eGFR > 30mL/min for participant with creatinine levels > 1.5 x ULN
    • Bilirubin ≤ 1.5 x IULN (except subjects with Gilbert Syndrome who can have total bilirubin ≥ 3.0 mg/dL)
    • Aspartate aminotransferase (AST) ≤ 3.0 x IULN
    • Alanine aminotransferase (ALT) ≤ 3.0 x IULN
    • Alkaline phosphatase ≤ 2.5 IULN
  13. Neuropathy (sensory and motor) Grade ≤ 1 (CTCAE v4)
  14. Females of childbearing potential must have a negative serum pregnancy test at screening and within 24 hours prior to initiation of study treatment. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.
  15. Females of childbearing potential and non-vasectomized males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 5 months after last dose of study drug (females) and 7 months after last dose of study drug for (males). The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.
  16. As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study

Exclusion Criteria:

  1. Patients with evidence of distant metastases (stage IV ocular melanoma) are not eligible.
  2. Patients with local or orbital recurrence are not eligible.
  3. Patients with cutaneous, mucosal, acral or conjunctival melanoma are not eligible.
  4. Subjects with active, known, or suspected autoimmune disease. Subjects with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment or conditions not expected to recur in the absences of an external trigger are permitted to enroll.
  5. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 2 years of study drug administration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  6. Participants with previous malignancies are excluded unless a complete remission was achieved at 12 months prior to study entry and no additional therapy is required or anticipated to be required during the study period (exceptions include but are not limited to, non-melanoma skin cancers; in situ bladder cancer, in situ gastric cancer, or in situ colon cancer; in situ cervical cancer/dysplasia; or breast carcinoma in situ).
  7. History of Grade ≥ 3 allergy to human monoclonal antibodies.
  8. Subjects who have had prior immunotherapy, including but not limited to interferon alfa-2b, PEG-IFN, anti-PD-1, anti-PD-L1, anti-CTLA4 intra-tumoral or vaccine therapies are not permitted to enroll.
  9. Psychological, familial, sociological, or geographical conditions that potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the participant before registration in the trial.
  10. Subjects who are receiving any other investigational agents.
  11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (requiring systemic therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  12. Patients known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Note: Testing for HIV must be performed at sites where mandated locally.
  13. Subjects who are unable or unwilling to discontinue use of prohibited medications.
  14. Subject is a prisoner

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03528408


Contacts
Layout table for location contacts
Contact: Ronald (Ron) Flores 202-687-9802 rf764@georgetown.edu
Contact: Donna Sullivan 317-634-5842 ext 40 dsullivan@hoosiercancer.org

Locations
Layout table for location information
United States, California
University of California San Francisco Recruiting
San Francisco, California, United States, 94158
Contact: Mario Velez    Phone: 415-353-7862 E-mail:    Mario.Velez@ucsf.edu   
Principal Investigator: Katy Tsai, MD         
United States, District of Columbia
Georgetown University Recruiting
Washington, District of Columbia, United States, 20057
Contact: Ronald (Ron) Flores    202-687-9802    rf764@georgetown.edu   
Principal Investigator: Suthee Rapisuwon, MD         
United States, Illinois
Northwestern Univeristy Feinberg School of Medicine Recruiting
Chicago, Illinois, United States, 60611
Contact: Ella Simionov    312-695-1350    gyongyi.simionov@northwestern.edu   
Principal Investigator: Sunandana Chandra, MD         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Jill Neu    314-454-8565    jneu@dom.wustl.edu   
Principal Investigator: Leonel Hernandez-Aya, MD         
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Lisa Olmos    212-342-5162    cancerclinicaltrials@cumc.columbia.edu   
Principal Investigator: Richard Carvajal, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Sapna P. Patel, MD    713-792-2921    melanoma@mdanderson.org   
Principal Investigator: Sapna P. Patel, MD         
Sponsors and Collaborators
Suthee Rapisuwon
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Suthee Rapisuwon, MD Georgetown University

Layout table for additonal information
Responsible Party: Suthee Rapisuwon, Sponsor-Investigator, Hoosier Cancer Research Network
ClinicalTrials.gov Identifier: NCT03528408    
Other Study ID Numbers: HCRN-MEL17-309
First Posted: May 17, 2018    Key Record Dates
Last Update Posted: November 18, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents